Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Comparison of Hyper-fractionated Accelerated and Standard Fractionated Radiotherapy with Concomitant Low-dose Gemcitabine for Unresectable Pancreatic Cancer

KOSEI MAEMURA, HIROYUKI SHINCHI, HIDETOSHI NOMA, YUKO MATAKI, HIROSHI KURAHARA, SHINICHI MAEDA, YOSHIYUKI HIRAKI, MASAYUKI NAKAJO, SHOJI NATSUGOE and SONSHIN TAKAO
Anticancer Research July 2008, 28 (4C) 2369-2372;
KOSEI MAEMURA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kmaemura@hotmail.co.jp
HIROYUKI SHINCHI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDETOSHI NOMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUKO MATAKI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI KURAHARA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINICHI MAEDA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIYUKI HIRAKI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAYUKI NAKAJO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHOJI NATSUGOE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SONSHIN TAKAO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Concurrent chemoradiotherapy with gemcitabine improves median survival for patients with unresectable pancreatic cancer. Recently, hyper-fractionated accelerated radiotherapy (HART) has been used to treat these patients; however, the safety and efficacy are not well defined. Patients and Methods: The standard-fractionated radiotherapy (SFRT) group (n=17) received 50.4 Gy in 28 fractions of 1.8 Gy/day. The HART group (n=18) received 50 Gy in 40 fractions of 1.25 Gy twice/day. Concurrent gemcitabine was administered to both groups. Results: Median survival times were 11.3 months (SFRT) and 12.9 months (HART). One- and two-year survival rates were 37.5% and 18.8% (SFRT) and 47.1% and 17.6% (HART), respectively. The response rates did not differ significantly. The HART regimen required significantly fewer treatment days (35.5) than did the SFRT regimen (41.3). The toxicity profiles were similar. Conclusion: The HART/gemcitabine regimen has equivalent efficacy and a shorter treatment time as compared with the SFRT/gemcitabine regimen for patients with unresectable pancreatic cancer.

  • Pancreas
  • unresectable cancer
  • chemoradiotherapy
  • hyper-fractionated accelerated radiotherapy
  • conformal radiotherapy
  • gemcitabine

Footnotes

  • Received January 29, 2008.
  • Revision received May 2, 2008.
  • Accepted May 6, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (4C)
Anticancer Research
Vol. 28, Issue 4C
July-August 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of Hyper-fractionated Accelerated and Standard Fractionated Radiotherapy with Concomitant Low-dose Gemcitabine for Unresectable Pancreatic Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Comparison of Hyper-fractionated Accelerated and Standard Fractionated Radiotherapy with Concomitant Low-dose Gemcitabine for Unresectable Pancreatic Cancer
KOSEI MAEMURA, HIROYUKI SHINCHI, HIDETOSHI NOMA, YUKO MATAKI, HIROSHI KURAHARA, SHINICHI MAEDA, YOSHIYUKI HIRAKI, MASAYUKI NAKAJO, SHOJI NATSUGOE, SONSHIN TAKAO
Anticancer Research Jul 2008, 28 (4C) 2369-2372;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Comparison of Hyper-fractionated Accelerated and Standard Fractionated Radiotherapy with Concomitant Low-dose Gemcitabine for Unresectable Pancreatic Cancer
KOSEI MAEMURA, HIROYUKI SHINCHI, HIDETOSHI NOMA, YUKO MATAKI, HIROSHI KURAHARA, SHINICHI MAEDA, YOSHIYUKI HIRAKI, MASAYUKI NAKAJO, SHOJI NATSUGOE, SONSHIN TAKAO
Anticancer Research Jul 2008, 28 (4C) 2369-2372;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers
  • Google Scholar

More in this TOC Section

  • Palliative Radiotherapy for Large Osteolytic Metastatic Tumors Involving the Iliac Bone: A Report of 16 Cases
  • Efficacy of Esophagectomy Following Neoadjuvant Chemotherapy for Esophageal Neuroendocrine Carcinoma
  • The Long-term Outcomes of Borderline Resectable T3 in Locally Advanced Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Triplet Chemotherapy
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire